U.S. Markets open in 8 hrs 24 mins

Ohr Pharmaceutical, Inc. (OHRP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.59-0.02 (-3.28%)
At close: 3:58PM EDT
People also watch

Ohr Pharmaceutical, Inc.

800 Third Avenue
11th Floor
New York, NY 10022
United States

Full Time Employees14

Key Executives

Dr. Jason Scott Slakter M.D.Chief Exec. Officer, Pres and Director375.19kN/A59
Mr. Samuel BackenrothChief Financial Officer and VP of Bus. Devel.324.12kN/A33
Dr. Avner Ingerman M.D.Chief Clinical Officer381.24kN/A53
Dr. Glenn L. Stoller M.D.Chief Scientific OfficerN/AN/A53
Dr. Peter K. Kaiser M.D.Head of Product Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Corporate Governance

Ohr Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.